Effect of Lenalidomide on Experimentally Induced Breast Cancer in Wistar Rats

Abstract

Breast cancer is one of the leading causes of death in women around the globe. In spite of modernization and readily accessible methods like self-examination, MMR and clinical diagnosis still breast cancer extracts a heavy toll in women s life next to lung cancer. Lenalidomide is an angiogenesis inhibitor with immune-modulatory properties and possess lesser toxicity when compared with Thalidomide and other teratogenic agents. In this study the anti-carcinogenic role and efficacy of Lenalidomide in experimentally induced breast cancer in rats was studied. newlineThe animals were divided into five group and Lenalidomide effect at two different doses were compared with Docetaxel effects. The study showed Lenalidomide group had a marked reduction in hematological parameter. This adverse effect is accounted for myelosuppression of Lenalidomide. newlineAn increase in oxidative enzyme levels was seen in treatment group. The histopathological study reveals ductal carcinoma induced by 7,12DMBA and reduction in malignant cells in Lenalidomide and Docetaxel treated group. Breast cancer management with Lenalidomide will have less teratogenicity unlike Thalidomide and more potent antioxidant, Immunomodulatory agent and also possess anti-angiogenic agent. In near future Lenalidomide can be combined with ER specific agents for broader anti-proliferative coverage in Breast cancer. newline newline